Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52

Yamasaki, Yoshioki; Satoh, Minoru; Mizushima, Machiko; Okazaki, Taro; Nagafuchi, Hiroko; Ooka, Seido; Shibata, Tomohiko; Nakano, Hiromasa; Ogawa, Hitoshi; Azuma, Kohei; Maeda, Akihiko; Tonooka, Kumiko; H, Ito; Takakuwa, Yukiko; Mitomi, Hirofumi; Kiyokawa, Tomofumi; Tsuchida, K.; Matsushita, Hiromi; Mikage, Hidenori; Murakami, Yoshihiko; Chan, Jason Y F; Ozaki, Shoichi; Yamada, Hisakata

doi:10.3109/14397595.2015.1091155

Cited by 39 publications

(42 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results confirm the frequencies of anti‐Mi2 and anti‐SAE antibodies, respectively, in 8.5% and 5.1% and are close to previous findings, respectively, in 9% (meta‐analysis) and 1% to 9% . In accordance with previous large series, we did not identify specific clinical features of DM and the risk of cancer or ILD in the presence of anti‐Mi2 or anti‐SAE antibodies …”

Section: Discussionsupporting

confidence: 92%

“…This might be due to our exclusive dermatological recruitment of patients as the presenting clinical features of the “antisynthetase syndrome” are myositis, ILD and arthritis, while cutaneous manifestations are mostly limited to Raynaud's phenomenon and mechanic's hands . Our results are in concordance with the data from previous studies reporting a significantly lower risk of eyelid involvement and, more globally, a less inflammatory cutaneous phenotype in patients DM with anti‐ARS antibodies …”

Section: Discussionsupporting

confidence: 91%

“…51,[65][66][67][68] Our results are in concordance with the data from previous studies reporting a significantly lower risk of eyelid involvement 14 and, more globally, a less inflammatory cutaneous phenotype in patients DM with anti-ARS antibodies. 64 Our results confirm the frequencies of anti-Mi2 and anti-SAE antibodies, respectively, in 8.5% and 5.1% and are close to previous findings, respectively, in 9% (meta-analysis) 64 and 1% 41 to 9%. 18 In accordance with previous large series, we did not identify specific clinical features of DM and the risk of cancer or ILD in the presence of anti-Mi2 9,17,19,21,26,35,36,68 or anti-SAE antibodies.…”

Section: Specific Antimyositis Antibodies In Adults With Dermatomyositissupporting

confidence: 90%

“…We identified anti-ARS antibodies in 5.1% of our patients, a lower frequency than in large series ranging from 8% 26 to 52%, 64 that were not associated with a previously described increased risk of ILD. 14,19,22,23,51 This might be due to our exclusive dermatological recruitment of patients as the presenting clinical features of the "antisynthetase syndrome" are myositis, 19,23,51 ILD and arthritis, 14,19,51 while cutaneous manifestations are mostly limited to Raynaud's phenomenon 64 and mechanic's hands. 51,[65][66][67][68] Our results are in concordance with the data from previous studies reporting a significantly lower risk of eyelid involvement 14 and, more globally, a less inflammatory cutaneous phenotype in patients DM with anti-ARS antibodies.…”

Section: Specific Antimyositis Antibodies In Adults With Dermatomyositiscontrasting

confidence: 57%

“…We identified anti‐ARS antibodies in 5.1% of our patients, a lower frequency than in large series ranging from 8% to 52%, that were not associated with a previously described increased risk of ILD . This might be due to our exclusive dermatological recruitment of patients as the presenting clinical features of the “antisynthetase syndrome” are myositis, ILD and arthritis, while cutaneous manifestations are mostly limited to Raynaud's phenomenon and mechanic's hands .…”

Section: Discussioncontrasting

confidence: 47%

See 4 more Smart Citations

Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients

Best

Jachiet

Molinari

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 91%

Section: Specific Antimyositis Antibodies In Adults With Dermatomyositissupporting

confidence: 90%

Section: Specific Antimyositis Antibodies In Adults With Dermatomyositiscontrasting

confidence: 57%

Section: Discussioncontrasting

confidence: 47%

See 3 more Smart Citations

Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients

Best

Jachiet

Molinari

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti‐aminoacyl‐tRNA synthetase antibodies: A single center experience

Zhang,

Wang,

Zhou

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectivesTo identify the differences of clinical characteristics, laboratory findings, and the long‐term outcomes in patients with anti‐synthetase syndrome (ASS) of different anti‐aminoacyl‐transfer RNA synthetase antibodies.MethodsWe retrospectively enrolled 119 patients with ASS, and the clinical characteristics and laboratory findings were collected. Additionally, multivariate COX regression analysis was performed to estimate the risk factors of prognosis in patients with ASS.ResultsThe frequency of interstitial lung disease (ILD) reached 93.3% in our cohort, of 28 (23.5%) was classified as rapidly progressive (RP)‐ILD. The highest incidence of RP‐ILD was 36.4% in the PL12 group of ASS patients. The ILD group was characterized by an older age, a lower prevalence of V sign, and a higher prevalence of pulmonary symptoms when contrasted with the non‐ILD group. There were statistical differences of clinical significance in arthritis, myositis, mechanic's hands, triad, shawl sign, V sign, and Raynaud's phenomenon among the four subgroups (all p < .05). Additionally, the prevalence rates of arthritis, myositis, mechanic's hands, triad, and V sign in the anti‐Jo1 antibody‐positive group were significantly higher than anti‐Jo1 antibody‐negative patients with ASS (all p < .05). Multivariate Cox regression analysis showed mechanic's hands (odds ratio [OR] = 6.47, p < .001), anti‐nuclear antibodies (ANA) (OR = 2.13, p = .026), ILD (OR = 10.50, p < .001), and V sign (OR = 0.30, p = .007) were independent factors affecting the prognosis of patients with ASS. The incidences of RP‐ILD, arthritis, myositis, triad, mechanic's hands, and shawl sign were more frequent in the anti‐Ro52 antibody‐positive group than the anti‐Ro52 antibody‐negative patients with ASS (all p < .05).ConclusionsPatients with ASS accompanied with ILD are highly prevalent. Mechanic's hands, ANA, and ILD may be a potential biomarker for predicting a poor prognosis in patients with ASS. Additionally, the detection of the anti‐Ro52 antibody provides valuable insights for managing and predicting disease progression and long‐term outcomes.

show abstract

Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis

Ceribelli¹,

Isailovic²,

Santis³

et al. 2016

Clin Rheumatol

View full text Add to dashboard Cite

This study aims to characterize myositis-specific antibodies in a well-defined cohort of patients with idiopathic inflammatory myopathy and to determine their association with cancer. Sera from 40 patients with polymyositis, dermatomyositis, and controls were tested by protein and RNA immunoprecipitation to detect autoantibodies, and immunoprecipitation-Western blot was used for anti-MJ/NXP-2, anti-MDA5, and anti-TIF1γ/α identification. Medical records were re-evaluated with specific focus on cancer. Anti-MJ/NXP-2 and anti-TIF1γ/α were the most common antibodies in dermatomyositis. In six dermatomyositis cases, we found five solid forms of cancer and one Hodgkin's lymphoma in long-term remission. Among patients with cancer-associated dermatomyositis, three were positive for anti-TIF1γ/α, two for anti-Mi-2, and one for anti-MJ/NXP-2. The strongest positivity of anti-TIF1γ was seen in two active forms of cancer, and this antibody was either negative or positive at low titers in the absence of cancer or in the 7-year remission Hodgkin's lymphoma. Four out of twenty (20 %) patients with polymyositis had solid cancer, but no specific association with autoantibodies was identified; further, none of the four cases of antisynthetase syndrome had a history of cancer. No serum myositis-associated autoantibody was observed in control sera, resulting in positive predictive value 75 %, negative predictive value 78.5 %, sensitivity 50 %, specificity 92 %, and area under the ROC curve 0.7083 for the risk of paraneoplastic DM in anti-TIF1γ/α (+) patients. Myositis-specific autoantibodies can be identified thanks to the use of immunoprecipitation, and their association with cancer is particularly clear for anti-TIF1γ/α in dermatomyositis. This association should be evaluated in a prospective study by immunoprecipitation in clinical practice.

show abstract

Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52

Abstract: Patients with different anti-ARS in combination with anti-Ro52 appear to be associated with distinctive clinical subsets.

Cited by 39 publications

References 29 publications

Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients

Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients

Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti‐aminoacyl‐tRNA synthetase antibodies: A single center experience

Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis

Contact Info

Product

Resources

About